Federal contract award
75F40123C00196
IN VITRO AND IN VIVO ASSESSMENT OF BUPRENORPHINE EXTENDED RELEASE INJECTIONS FOR GENERIC PRODUCT EQUIVALENCE
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | B504 — Chemical/Biological Studies and Analysis |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $876.4K |
| Current contract value | $876.4K |
| Potential contract value / ceiling | $876.4K |
| Start date | Sep 21, 2023 |
| Current end date | Sep 29, 2026 |
| Potential end date | Sep 29, 2026 |
| Latest award activity | Jul 9, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 4 of 4 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 9, 2025 | P00003 | $0 | NO COST MODIFICATION TO CHANGE THE PERIOD OF PERFORMANCE END DATE TO SEPTEMBER 29, 2026. |
| Jul 20, 2024 | P00002 | $323.4K | IN VITRO AND IN VIVO ASSESSMENT OF BUPRENORPHINE EXTENDED RELEASE INJECTIONS FOR GENERIC PRODUCT EQUIVALENCE |
| Dec 12, 2023 | P00001 | $0 | IN VITRO AND IN VIVO ASSESSMENT OF BUPRENORPHINE EXTENDED RELEASE INJECTIONS FOR GENERIC PRODUCT EQUIVALENCE |
| Sep 21, 2023 | 0 | $552.9K | IN VITRO AND IN VIVO ASSESSMENT OF BUPRENORPHINE EXTENDED RELEASE INJECTIONS FOR GENERIC PRODUCT EQUIVALENCE |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.